8-K: Serina Therapeutics Reports First Quarter 2024 Results and Provides Business Update

Serina Therapeutics announced its first quarter 2024 financial results, highlighting the advancement of its lead drug candidate and the completion of its merger with AgeX Therapeutics.

Summary

• Serina Therapeutics reported its financial results for the quarter ended March 31, 2024, which included a net loss of $9.4 million, or ($3.38) per share, compared to a net income of $1.7 million in the same period of 2023.
• The company's operating expenses increased to $2.3 million from $1 million in the first quarter of 2023, with research and development expenses rising to $1.1 million and general and administrative expenses reaching $1.2 million.
• The increase in expenses was primarily due to costs associated with the merger with AgeX Therapeutics, which closed on March 26, 2024, and changes in the fair value of convertible promissory notes.
• Revenues for the quarter were $5,000, down from $30,000 in the same period last year, consisting entirely of grant revenues.
• The company's cash, cash equivalents, and restricted cash totaled $8.8 million as of March 31, 2024, and it owed Juvenescence Limited $10.4 million in principal and origination fees.
• Serina is advancing its lead drug candidate, SER-252, for Parkinson's disease and plans to submit an Investigational New Drug (IND) application to the FDA with a Phase 1 clinical trial planned for 2025.
• The company also increased its line of credit with Juvenescence Limited by $2.4 million on March 26, 2024, and an additional $525,000 on May 8, 2024.

Sentiment

Score: 3

Explanation: The document presents a mixed picture with significant financial losses and going concern issues, offset by positive developments in drug development and leadership. The overall sentiment is negative due to the financial challenges.

Positives

• Serina is advancing its lead drug candidate, SER-252, for Parkinson's disease, with plans to initiate a Phase 1 clinical trial in 2025.
• The company successfully completed its merger with AgeX Therapeutics, which provides a new strategic direction.
• The appointment of Dr. Simba Gill as Executive Chairman brings significant biotech and pharma experience to the company.
• The company secured additional funding through an increased line of credit with Juvenescence Limited.

Negatives

• The company reported a significant net loss of $9.4 million for the first quarter of 2024.
• Operating expenses have more than doubled compared to the same period last year.
• The company's revenues decreased significantly to $5,000 from $30,000 in the first quarter of 2023.
• The company has a substantial debt of $10.4 million owed to Juvenescence Limited.
• The company's cash balance of $8.8 million may not be sufficient to meet its operating and funding requirements for the next twelve months, raising concerns about its ability to continue as a going concern.

Risks

• The company's ability to continue as a going concern is in doubt due to insufficient cash to meet its operating and funding requirements for the next twelve months.
• The company is subject to the risks inherent in research and development, including the ability to meet anticipated clinical endpoints and regulatory approval dates.
• The company's financial results are subject to uncertainties, including the impact of COVID-19 and competitive developments.
• The company's reliance on a line of credit from Juvenescence Limited exposes it to potential financial risks.

Future Outlook

The company plans to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration and initiate a Phase 1 clinical trial for SER-252 in 2025. Serina also intends to advance additional applications of the POZ platform via out-licensing, co-development, or other partnership arrangements.

Management Comments

• The management team of the combined company is led by Steven Ledger as Interim Chief Executive Officer.
• Dr. Gill will play a pivotal role in guiding Serina through its next phase of growth and development, leveraging his expertise to drive strategic expansion initiatives.

Industry Context

The announcement reflects the ongoing challenges and opportunities in the biotechnology sector, particularly for companies focused on drug delivery technologies and clinical-stage development. The merger and new leadership aim to position Serina for growth in a competitive market.

Comparison to Industry Standards

• The increase in operating expenses, particularly in R&D and G&A, is typical for a clinical-stage biotech company advancing its pipeline, however the magnitude of the increase is significant.
• The net loss of $9.4 million is substantial for a company of this size and stage, and is worse than many comparable companies at a similar stage of development.
• The company's cash balance of $8.8 million is relatively low for a company planning to initiate a Phase 1 clinical trial, and is lower than many comparable companies.
• The reliance on a line of credit from Juvenescence Limited is not uncommon for early-stage biotech companies, but the amount of debt is significant.
• The company's technology platform, POZ, is similar to other drug delivery technologies being developed by companies such as Selecta Biosciences and BIND Therapeutics, but the specific applications and clinical results will determine its competitive position.

Management Changes

Related Party Transactions

• The company has a line of credit with Juvenescence Limited, with a total outstanding balance of $10.4 million as of March 31, 2024.

Stakeholder Impact

• Shareholders will be concerned about the significant net loss and the company's going concern issues.
• Employees may be affected by the company's financial challenges and potential restructuring.
• Customers and partners may be impacted by the company's ability to continue its operations and development programs.
• Creditors, particularly Juvenescence Limited, will be closely monitoring the company's financial situation.

Next Steps

• The company plans to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration for SER-252.
• The company plans to initiate a Phase 1 clinical trial for SER-252 in 2025.
• The company intends to advance additional applications of the POZ platform via out-licensing, co-development, or other partnership arrangements.

Key Dates

Keywords

Serina Therapeutics, POZ Platform, SER-252, Parkinson's Disease, Clinical Trial, Merger, Biotechnology, Drug Delivery, Financial Results, Juvenescence Limited